Suggested remit: To appraise the clinical and cost effectiveness nemolizumab within its marketing authorisation for treating prurigo nodularis in adults
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Further information Status change linked to Topic Selection Decision being set to Selected.
Process STA Standard
ID number 6451

Provisional Schedule

Committee meeting: 1 05 March 2025
Expected publication 21 May 2025

Project Team

Project lead Jeremy Powell

Email enquiries

External Assessment Group Health Economics Research Unit and Health Services Research Unit, University of Aberdeen

Stakeholders

Companies sponsors Galderma (nemolizumab)
Others Department of Health and Social Care
  NHS England
Patient carer groups Allergy UK
  Changing Faces
  Eczema Outreach Support
  Let’s Face It
  National Eczema Society
  Prurigo Nodularis International
  South Asian Health Foundation
  Specialised Healthcare Alliance
Professional groups British Association of Dermatologists
  British Dermatological Nursing Group
  British Geriatrics Society
  British Society for Cutaneous Allergy
  Primary Care Dermatology Society
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  St John’s Institute of Dermatology
  UK Clinical Pharmacy Association
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Advanz Pharma (methotrexate)
  Aspen (azathioprine)
  Bristol Myers Squibb (thalidomide)
  Cipla UK (methotrexate)
  Dexcel pharma (ciclosporin)
  Hospira (methotrexate)
  Medac (methotrexate)
  Morningside Healthcare (methotrexate)
  Mylan (azathioprine; ciclosporin)
  Nordic Pharma (methotrexate)
  Nova (azathioprine)
  Novartis Pharmaceuticals (ciclosporin)
  Orion Pharma (methotrexate)
  Rosemont Pharmaceuticals (methotrexate)
  Sandoz (methotrexate)
  Santen UK (ciclosporin)
  Strides Pharma (azathioprine)
  Tillomed Laboratories (azathioprine)
  Zentiva (thalidomide)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health - Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups British Skin Foundation
  Centre of Evidence-based Dermatology, University of Nottingham
  Cochrane Skin Group
  Dermatrust
  Genomics England
  MRC Clinical Trials Unit
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
31 July 2024 Invitation to participate
18 June 2024 Please note ID6451 indication is now a separate appraisal from ID6221 indication. The appraisal will be running on the same timelines as ID6221. Please see relevant topic webpages for further information.
09 May 2024 - 07 June 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
09 May 2024 In progress. Scoping commenced.
18 November 2022 Awaiting development

For further information on our processes and methods, please see our CHTE processes and methods manual